The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

IX.r

Myasthenia gravis - Myasthenic-like syndrome

Publications

Fazal M, Prentice DA, Kho LK, Fysh E

Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.

Internal medicine journal 2020 Aug;50;1003-1006 — 2020 Aug — 1003-1006

de Chabot G, Justeau G, Pinquié F, Nadaj-Pakleza A, Hoppé E, Hureaux J, Urban T

[Unexpected adverse events of immunotherapies in non-small cell lung cancer: About 2 cases].

Revue de pneumologie clinique 2017 Dec;73;326-330 — 2017 Dec — 326-330

Mehta JJ, Maloney E, Srinivasan S, Seitz P, Cannon M

Myasthenia Gravis Induced by Nivolumab: A Case Report.

Cureus 2017 Sep 20;9;e1702 — 2017 Sep 20 — e1702

Fukasawa Y, Sasaki K, Natsume M, Nakashima M, Ota S, Watanabe K, Takahashi Y, Kondo F, Kozuma K, Seki N

Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis.

Case reports in oncology 2017 Sep-Dec;10;809-812 — 2017 Sep-Dec — 809-812

Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M

Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.

Neurology 2017 Sep 12;89;1127-1134 — 2017 Sep 12 — 1127-1134

Hasegawa Y, Kawai S, Ota T, Tsukuda H, Fukuoka M

Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review.

Immunotherapy 2017 08;9;701-707 — 2017 08 — 701-707

Chang E, Sabichi AL, Sada YH

Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder.

Journal of immunotherapy (Hagerstown, Md. : 1997) 2017 04;40;114-116 — 2017 04 — 114-116

Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, Ando Y, Matsukawa M, Inoue H, Kiyotani K, Park JH, Nakamura Y, Ihn H

Myasthenic crisis and polymyositis induced by one dose of nivolumab.

Cancer science 2016 Jul;107;1055-8 — 2016 Jul — 1055-8

Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, Katoh N, Nishie K, Okuyama R, Uhara H

Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.

Japanese journal of clinical oncology 2016 Jan;46;86-8 — 2016 Jan — 86-8

Loochtan AI, Nickolich MS, Hobson-Webb LD

Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer.

Muscle & nerve 2015 Aug;52;307-8 — 2015 Aug — 307-8